Hexyl acetate

Endpoint summary

Description of key information

Subchronic exposure of rats to n-butyl acetate vapour resulted in acute, transient signs of reduced activity levels during exposure to 1500 and 3000 ppm. Decreased body weight and feed consumption were noted for the 1500 and 3000 ppm groups, but there was no systemic or organ-specific toxicity. Signs of upper respiratory tract irritation were seen in the nasal passages of 1500 and 3000 ppm animals, but there was no evidence of pulmonary toxicity. The no-observed-adverse-effect concentration (NOAEC) for this study is considered to be 500 ppm (2.4 mg/L).

Key value for chemical safety assessment

Repeated dose toxicity: via oral route - systemic effects

Endpoint conclusion

Endpoint conclusion:

no study available

Repeated dose toxicity: inhalation - systemic effects

Link to relevant study records

Reference

Endpoint:

sub-chronic toxicity: inhalation

Type of information:

migrated information: read-across from supporting substance (structural analogue or surrogate)

Adequacy of study:

key study

Study period:

12 September 1994 to 16 August 1996

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: Modern, guideline Study (EPA OTS 798.2450)

Qualifier:

according to guideline

Guideline:

EPA OTS 798.2450 (90-Day Inhalation Toxicity)

Deviations:

no

Principles of method if other than guideline:

Standard subchronic assessment of inhalation exposure according to EPA test guidelines

GLP compliance:

yes

Limit test:

no

Species:

rat

Strain:

Sprague-Dawley

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: Charles River Kingston (Stone ridge, NY)
- Age at study initiation: 60 days
- Weight at study initiation: 271 +/- 7 g (males); 215 +/- 8 g (females)
- Fasting period before study: no
- Housing: individually during non expsure periods
- Diet: Certified Rodent Diet (Agway Prolab RMH 3200, ground chow), ad libitum except during exposure
- Water: ad libitum, except during exposure
- Acclimation period: 12 days


ENVIRONMENTAL CONDITIONS
- Temperature: 67-75°F
- Humidity: 46-60%
- Photoperiod (hrs dark / hrs light): 12/12

Route of administration:

inhalation: vapour

Type of inhalation exposure:

whole body

Vehicle:

other: unchanged (no vehicle)

Remarks on MMAD:

MMAD / GSD: No details for MMAD, the vapour concentration was estimated .

Details on inhalation exposure:

GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: 4200 L stainless-steel and glass inhalation chambers
- Method of holding animals in test chamber: cages
- System of generating vapour: test substance was metered into glass distillation columns packed with glass beads; filtered, compressed air was passed through the glass bead-packed columns to evaporate the test substance; distillation columns were heated to about 50°C to enhance vaporization; the resultant vapour was directed via glass tubing to a tee just upstream of the inhalation chamber where it was mixed with filtered, conditioned outside air
- Temperature, humidity in air chamber: 21.1-24.7°C; 36.7-68.7%
- Air flow rate: 836 to 965 Lpm
- Air change rate: 12 to 14 air changes per hour
- Method of particle size determination: Micro Laser Particle counter (µLPC-301, Particle Measuring Systems, Inc, Coulder, USA); indicating that an aerosol of the test subsance was not present

Analytical verification of doses or concentrations:

yes

Details on analytical verification of doses or concentrations:

- MIRAN IA infrared gas analyzer (Wilks Foxboro Analytical, South Norwalk, CT) set at a wavelength of 3.38 µM
- chamber vapour samples were continuously collected from each chamber throught TEFLON tubing (3/16" i.d.)
- valve position was periodically changed to sample from each chamber at least once each hour

Duration of treatment / exposure:

13 weeks

Frequency of treatment:

6 hours per day, 5 days per week

Remarks:

Doses / Concentrations:
500, 1500, 3000 ppm
Basis:
nominal conc.

No. of animals per sex per dose:

15

Control animals:

yes, sham-exposed

Details on study design:

- Dose selection rationale: Range finding study: 2-Weeks repeated exposure in which animals were exposed to 0, 750, 1500 or 3000 ppm n-butyl acetate. The test substance produced concentration-related reductions in general activity levels during exposure periods. Animals appeared to acclimate to the 750 and 1500 ppm concentrations but not to 3000 ppm. Mean body weights for the female 1500 ppm animals and for the 3000 ppm male and female animals were lower than the control group on Days 7 and 14, but no statistically significant differences were noted. 3000 ppm was selected as an exposure concentration that would produce overt signs of toxicity, and 500 ppm was selected as an exposure concentration that was expected to have no effect. An exposure concentration of 1500 ppm was selected as the intermediate exposure concentration.

Positive control:

No

Observations and examinations performed and frequency:

CAGE SIDE OBSERVATIONS: Yes
- Time schedule: during exposure and once per day on weekends
- Cage side observations checked were included.


DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: before and after exposure


BODY WEIGHT: Yes
- Time schedule for examinations: weekly


FOOD CONSUMPTION: YES
- Time schedule for examinations: weekly

FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No


WATER CONSUMPTION: No


OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: prior to the start of the study and during the last week of exposure
- Dose groups that were examined: all animals prior to the start of the study; animals from the control and high-concentration group during the last week of exposure


HAEMATOLOGY: Yes
- Time schedule for collection of blood: day 30 and 90 of the study
- Anaesthetic used for blood collection: Yes (Metofane)
- Animals fasted: Yes
- How many animals: 5 per sex per dose group
- Parameters checked:
Whole blood: hemoglobin concentration, red blood cell count, white blood cell count, hematocrit, red blood cell indices, prothrombin time
Blood smears: cellular morphology and differential white blood cell count


CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: day 30 and 90 of the study
- Anaesthetic used for blood collection: Yes (Metofane)
- Animals fasted: Yes
- How many animals: 5 per sex per dose group
- Parameters checked:
Blood serum: aspartate aminotransferase, sorbitol dehydrogenase, alkaline phosphatase, creatinine, albumin, total protein, total bilirubin, alanine aminotransferase, gamma glutamyltranspeptidase, urea nitrogen, glucose, calcium, phosphorus


URINALYSIS: No

NEUROBEHAVIOURAL EXAMINATION: No

OTHER: Organ weights (liver, kidneys, testes or ovaries, spleen adrenal glands, lungs, brain)

Sacrifice and pathology:

GROSS PATHOLOGY: Yes

HISTOPATHOLOGY: Yes (embedded in paraffin, sectioned at 5 µm and stained with hematoxylin and eosin; nasal passages were decalcified prior to being embedded and sectioned); all tissues (see below) were examined microscopically from the control and high-concentration groups, in addition, the lungs, nasal passages, thymus (males only), stomach (females only), and gross lesions were examined from the mid- and low concentration group
- tissues examined: nasal passages, trachea, larynx, lungs, esophagus, stomach, duodenum, jejunum, ileum, cecum, colon, rectum, heart, aorta, adrenal glands, pituitary gland, thymus, pancreas, urinary bladder, thyroid gland, parathyroid gland, spleen, liver, kidneys, mesenteric lymph nodes, sternum (with bone marrow), right testis, right epididymis, male accessory sex glands, ovaries, vagina, uterus, fallopian tubes, salivary glands, gross lesions

Other examinations:

- assessment of sperm morphology and development

Statistics:

Bartlett's test, one-way analysis of variance, Duncan's multiple range test, Kruskal-Wallis H-test and Mann-Whitney U-test

Clinical signs:

effects observed, treatment-related

Mortality:

mortality observed, treatment-related

Body weight and weight changes:

effects observed, treatment-related

Food consumption and compound intake (if feeding study):

effects observed, treatment-related

Food efficiency:

not specified

Water consumption and compound intake (if drinking water study):

not specified

Ophthalmological findings:

no effects observed

Haematological findings:

effects observed, treatment-related

Clinical biochemistry findings:

effects observed, treatment-related

Urinalysis findings:

not examined

Behaviour (functional findings):

not examined

Organ weight findings including organ / body weight ratios:

effects observed, treatment-related

Gross pathological findings:

effects observed, treatment-related

Histopathological findings: non-neoplastic:

effects observed, treatment-related

Histopathological findings: neoplastic:

not examined

Details on results:

CLINICAL SIGNS AND MORTALITY
- no spontaneous mortality occurred during the study

3000 ppm group:
- reduced activity levels of generally minor severity during exposure (less movement, decreased alertness, slower response to tapping on the chamber wall)
- Sialorrhea was observed in three animals for no more than one or two exposure days
- red discoloration of the chin hair occurred in several females for no more than one or two exposure days

1500 ppm group:
- reduced activity of generally minimal severity during exposure periods (exceüpt the first 5 hours of Day 0 and the first hour or two of Days 1 and 2)

Animals in all groups had prophyrin nasal discharges and dried porphyrin stains around the nose, which occasionally persisted till the next morning. Animals from all groups exhibited discolored-red facial hair, usually the chin hair (slightly higher in the 3000 ppm group than in other groups)

BODY WEIGHT AND WEIGHT GAIN

3000 ppm group:
- significantly reduced mean body weights and body weight gains in males and females; overall weight gains were 62% and 78% of weight gains for the control group (males and females, respectively)

1500 ppm group:
- significantly reduced mean body weights and body weight gains in males and females; overall weight gains were 77% and 70% of weight gains for the control group (males and females, respectively)

500 ppm group:
- body weights and body weight gains were not affected; overall weight gains were 90% and 107% of weight gains for the control group (males and females, respectively)

FOOD CONSUMPTION

3000 ppm group:
- significantly lower than for the control group
- mean weekly feed consumption values were 14-25% or 6-16% lower than the control group in male and female rats, respectively

1500 ppm group:
- significantly lower than for the control group
- mean weekly feed consumption values were 4-17% or 10-15% lower than the control group in male and female rats, respectively
500 ppm group:
- significantly (p - mean weekly feed consumption values were 3-12% lower than the control group in male rats and from 2% higher to 7% lower than the control group for female rats
FOOD EFFICIENCY
- no data

WATER CONSUMPTION
- no data

OPHTHALMOSCOPIC EXAMINATION
- no effects

HAEMATOLOGY
No significant differences in hematologic parameters were seen after 30 days on test. Significantly higher (p Evaluation of blood cell morphology did not suggest any compound-related effects. After 30 days on test, spherocytosis and poikilocytosis were seen in blood smears of animals from most groups. Increased polychromasia was observed in one male control rat (# 613), while decreased polychromasia was see in two female 3000 ppm rats (# 719 and 720). Howell-Jolly bodies in the blood and anisocytosis were also noted for Rat # 720. After 90 days on test, poikilocytosis was seen in animals from all groups. Anisocytosis was noted in animals from the control, 500, and 1500 ppm groups. Microcytosis was seen in one male 1500 ppm rat (# 632) and in one male 500 ppm rat (#624) and spherocytosis was seen in two male 1500 ppm rats (# 631 and 638).

CLINICAL CHEMISTRY
After 30 days on test, mean sodium concentrations for the male and female 3000 ppm groups were significantly lower (p After 90 days on test, mean albumin and total protein concentrations for the 3000 ppm female group were significantly lower (p
URINALYSIS
- not examined

NEUROBEHAVIOUR
- not examined

ORGAN WEIGHTS
Mean terminal body weights measured after exsanguination were significantly lower (p kidney weights for the 1500 female and 3000 ppm male and female groups were also significantly lower (p

GROSS PATHOLOGY
- no exposure related effects were observe in male rats.
- Two females of the 3000 ppm group showed hemorrhage involving the glandular stomach (minimal severity). White discoloration in the non-glandular stomach was also observe for these animals.
- No changes were seen in female rats from the 1500 and 500 ppm groups.

HISTOPATHOLOGY: NON-NEOPLASTIC
- exposure related changes were observed in the nasal passages and stomach of 1500 and 3000 ppm rats
- all male and female 3000 ppm rats and 4/10 male and 6/10 female 1500 ppm rats had necrosis of the olfactory epithelium (mild to moderate for the 3000 ppm group, mild for the 1500 ppm group).
- no lesions were observed in the nasal passages of the 500 ppm group
- 3/10 female rats of the 3000 ppm group had inflammation of the stomach mucosa (glandular or forestomach) of mild to minimal severity; the pathologist concluded that this effect was probably due to stress
- no effects were seen in the low- and mid concentration group
- thymus atrophy was observed in one male of the 3000 ppm group, this lesion was attributed to stress by the pathologist

HISTOPATHOLOGY: NEOPLASTIC (if applicable)
- not examined


OTHER FINDINGS
- No exposure-related effect on epidydimidal or testicular sperm count was observed. Effects on testicular staging or spermatogenic were not evaluated due to the unacceptable condition of tissue.

Dose descriptor:

NOAEC

Effect level:

500 ppm

Based on:

test mat.

Sex:

male/female

Basis for effect level:

other: see 'Remark'

Critical effects observed:

not specified

- overall time-weighted average analytical concentrations:

548.4; 1487.5, 3009.6 ppm for males

547.9, 1487.6, 3008.8 ppm for females

- target analytical concentration for the 500 ppm group was increased to 550 ppm to ensure that exposure concentration was at least 500 ppm at all locations of the eposure chamber

Conclusions:

The no-observed-adverse-effect concentration (NOAEC) for this study is considered to be 500 ppm (2.4 mg/L).

Executive summary:

Male and female Sprague-Dawley rats (15 animals/sex/dose group) were exposed to nominal concentrations of 0, 500, 1500 or 3000 ppm of n-butyl acetate for 6 hours per day, 5 days per week for 13 consecutive weeks. The time-weighted average analytical concentrations were within 10% of the target concentrations. Transient signs of sedation were observed during exposure to the 1500 and 3000 ppm concentrations. Body weights were significantly reduced in the mid and high concentration groups. Feed consumption was significantly lower in the 1500 and 3000 ppm group in comparison to the control group. Organ weights affected: weights of liver, kidneys and spleen were significantly lower for the males of the highest concentration goup. Testes and adrenal gland weights for the mid and high concentration groups and the lung weights for the 3000 ppm males were significantly higher than for the control group. Additionally, effects on the stomach (probably stress related) and pulmonary system were observed: Females of the highest concentration group showed signs of irritation of the glandular stomach and necrosis in the non-glandular stomach. Some rats of the 1500 and 3000 ppm group showed degeneration of the olfactory epithelium along the dorsal medial meatus and ethmotubinates of the nasal passages. The severity was mild to moderate for the 3000 ppm group and minimal to mild for the 1500 ppm group. There was no systemic, organ specific toxicity. The no-observed-adverse-effect concentration (NOAEC) for this study is 500 ppm (2.4 mg/L).

Long term local respiratory tract irritation was also apparent at the two higher dose levels in this study but no local effects were identified in the 500 ppm (NOAEC) group.

Endpoint conclusion

Endpoint conclusion:

adverse effect observed

Dose descriptor:

NOAEC

2 400 mg/m³

Study duration:

subchronic

Species:

rat

Quality of whole database:

A reliable modern guideline-compliant 90-day study is supported by a reliable dose-ranging study; studies were performed using the read-across substance n-butyl acetate.

Repeated dose toxicity: inhalation - local effects

Link to relevant study records

Reference

Endpoint:

sub-chronic toxicity: inhalation

Type of information:

migrated information: read-across from supporting substance (structural analogue or surrogate)

Adequacy of study:

key study

Study period:

12 September 1994 to 16 August 1996

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: Modern, guideline Study (EPA OTS 798.2450)

Qualifier:

according to guideline

Guideline:

EPA OTS 798.2450 (90-Day Inhalation Toxicity)

Deviations:

no

Principles of method if other than guideline:

Standard subchronic assessment of inhalation exposure according to EPA test guidelines

GLP compliance:

yes

Limit test:

no

Species:

rat

Strain:

Sprague-Dawley

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: Charles River Kingston (Stone ridge, NY)
- Age at study initiation: 60 days
- Weight at study initiation: 271 +/- 7 g (males); 215 +/- 8 g (females)
- Fasting period before study: no
- Housing: individually during non expsure periods
- Diet: Certified Rodent Diet (Agway Prolab RMH 3200, ground chow), ad libitum except during exposure
- Water: ad libitum, except during exposure
- Acclimation period: 12 days


ENVIRONMENTAL CONDITIONS
- Temperature: 67-75°F
- Humidity: 46-60%
- Photoperiod (hrs dark / hrs light): 12/12

Route of administration:

inhalation: vapour

Type of inhalation exposure:

whole body

Vehicle:

other: unchanged (no vehicle)

Remarks on MMAD:

MMAD / GSD: No details for MMAD, the vapour concentration was estimated .

Details on inhalation exposure:

GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: 4200 L stainless-steel and glass inhalation chambers
- Method of holding animals in test chamber: cages
- System of generating vapour: test substance was metered into glass distillation columns packed with glass beads; filtered, compressed air was passed through the glass bead-packed columns to evaporate the test substance; distillation columns were heated to about 50°C to enhance vaporization; the resultant vapour was directed via glass tubing to a tee just upstream of the inhalation chamber where it was mixed with filtered, conditioned outside air
- Temperature, humidity in air chamber: 21.1-24.7°C; 36.7-68.7%
- Air flow rate: 836 to 965 Lpm
- Air change rate: 12 to 14 air changes per hour
- Method of particle size determination: Micro Laser Particle counter (µLPC-301, Particle Measuring Systems, Inc, Coulder, USA); indicating that an aerosol of the test subsance was not present

Analytical verification of doses or concentrations:

yes

Details on analytical verification of doses or concentrations:

- MIRAN IA infrared gas analyzer (Wilks Foxboro Analytical, South Norwalk, CT) set at a wavelength of 3.38 µM
- chamber vapour samples were continuously collected from each chamber throught TEFLON tubing (3/16" i.d.)
- valve position was periodically changed to sample from each chamber at least once each hour

Duration of treatment / exposure:

13 weeks

Frequency of treatment:

6 hours per day, 5 days per week

Remarks:

Doses / Concentrations:
500, 1500, 3000 ppm
Basis:
nominal conc.

No. of animals per sex per dose:

15

Control animals:

yes, sham-exposed

Details on study design:

- Dose selection rationale: Range finding study: 2-Weeks repeated exposure in which animals were exposed to 0, 750, 1500 or 3000 ppm n-butyl acetate. The test substance produced concentration-related reductions in general activity levels during exposure periods. Animals appeared to acclimate to the 750 and 1500 ppm concentrations but not to 3000 ppm. Mean body weights for the female 1500 ppm animals and for the 3000 ppm male and female animals were lower than the control group on Days 7 and 14, but no statistically significant differences were noted. 3000 ppm was selected as an exposure concentration that would produce overt signs of toxicity, and 500 ppm was selected as an exposure concentration that was expected to have no effect. An exposure concentration of 1500 ppm was selected as the intermediate exposure concentration.

Positive control:

No

Observations and examinations performed and frequency:

CAGE SIDE OBSERVATIONS: Yes
- Time schedule: during exposure and once per day on weekends
- Cage side observations checked were included.


DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: before and after exposure


BODY WEIGHT: Yes
- Time schedule for examinations: weekly


FOOD CONSUMPTION: YES
- Time schedule for examinations: weekly

FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No


WATER CONSUMPTION: No


OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: prior to the start of the study and during the last week of exposure
- Dose groups that were examined: all animals prior to the start of the study; animals from the control and high-concentration group during the last week of exposure


HAEMATOLOGY: Yes
- Time schedule for collection of blood: day 30 and 90 of the study
- Anaesthetic used for blood collection: Yes (Metofane)
- Animals fasted: Yes
- How many animals: 5 per sex per dose group
- Parameters checked:
Whole blood: hemoglobin concentration, red blood cell count, white blood cell count, hematocrit, red blood cell indices, prothrombin time
Blood smears: cellular morphology and differential white blood cell count


CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: day 30 and 90 of the study
- Anaesthetic used for blood collection: Yes (Metofane)
- Animals fasted: Yes
- How many animals: 5 per sex per dose group
- Parameters checked:
Blood serum: aspartate aminotransferase, sorbitol dehydrogenase, alkaline phosphatase, creatinine, albumin, total protein, total bilirubin, alanine aminotransferase, gamma glutamyltranspeptidase, urea nitrogen, glucose, calcium, phosphorus


URINALYSIS: No

NEUROBEHAVIOURAL EXAMINATION: No

OTHER: Organ weights (liver, kidneys, testes or ovaries, spleen adrenal glands, lungs, brain)

Sacrifice and pathology:

GROSS PATHOLOGY: Yes

HISTOPATHOLOGY: Yes (embedded in paraffin, sectioned at 5 µm and stained with hematoxylin and eosin; nasal passages were decalcified prior to being embedded and sectioned); all tissues (see below) were examined microscopically from the control and high-concentration groups, in addition, the lungs, nasal passages, thymus (males only), stomach (females only), and gross lesions were examined from the mid- and low concentration group
- tissues examined: nasal passages, trachea, larynx, lungs, esophagus, stomach, duodenum, jejunum, ileum, cecum, colon, rectum, heart, aorta, adrenal glands, pituitary gland, thymus, pancreas, urinary bladder, thyroid gland, parathyroid gland, spleen, liver, kidneys, mesenteric lymph nodes, sternum (with bone marrow), right testis, right epididymis, male accessory sex glands, ovaries, vagina, uterus, fallopian tubes, salivary glands, gross lesions

Other examinations:

- assessment of sperm morphology and development

Statistics:

Bartlett's test, one-way analysis of variance, Duncan's multiple range test, Kruskal-Wallis H-test and Mann-Whitney U-test

Clinical signs:

effects observed, treatment-related

Mortality:

mortality observed, treatment-related

Body weight and weight changes:

effects observed, treatment-related

Food consumption and compound intake (if feeding study):

effects observed, treatment-related

Food efficiency:

not specified

Water consumption and compound intake (if drinking water study):

not specified

Ophthalmological findings:

no effects observed

Haematological findings:

effects observed, treatment-related

Clinical biochemistry findings:

effects observed, treatment-related

Urinalysis findings:

not examined

Behaviour (functional findings):

not examined

Organ weight findings including organ / body weight ratios:

effects observed, treatment-related

Gross pathological findings:

effects observed, treatment-related

Histopathological findings: non-neoplastic:

effects observed, treatment-related

Histopathological findings: neoplastic:

not examined

Details on results:

CLINICAL SIGNS AND MORTALITY
- no spontaneous mortality occurred during the study

3000 ppm group:
- reduced activity levels of generally minor severity during exposure (less movement, decreased alertness, slower response to tapping on the chamber wall)
- Sialorrhea was observed in three animals for no more than one or two exposure days
- red discoloration of the chin hair occurred in several females for no more than one or two exposure days

1500 ppm group:
- reduced activity of generally minimal severity during exposure periods (exceüpt the first 5 hours of Day 0 and the first hour or two of Days 1 and 2)

Animals in all groups had prophyrin nasal discharges and dried porphyrin stains around the nose, which occasionally persisted till the next morning. Animals from all groups exhibited discolored-red facial hair, usually the chin hair (slightly higher in the 3000 ppm group than in other groups)

BODY WEIGHT AND WEIGHT GAIN

3000 ppm group:
- significantly reduced mean body weights and body weight gains in males and females; overall weight gains were 62% and 78% of weight gains for the control group (males and females, respectively)

1500 ppm group:
- significantly reduced mean body weights and body weight gains in males and females; overall weight gains were 77% and 70% of weight gains for the control group (males and females, respectively)

500 ppm group:
- body weights and body weight gains were not affected; overall weight gains were 90% and 107% of weight gains for the control group (males and females, respectively)

FOOD CONSUMPTION

3000 ppm group:
- significantly lower than for the control group
- mean weekly feed consumption values were 14-25% or 6-16% lower than the control group in male and female rats, respectively

1500 ppm group:
- significantly lower than for the control group
- mean weekly feed consumption values were 4-17% or 10-15% lower than the control group in male and female rats, respectively
500 ppm group:
- significantly (p - mean weekly feed consumption values were 3-12% lower than the control group in male rats and from 2% higher to 7% lower than the control group for female rats
FOOD EFFICIENCY
- no data

WATER CONSUMPTION
- no data

OPHTHALMOSCOPIC EXAMINATION
- no effects

HAEMATOLOGY
No significant differences in hematologic parameters were seen after 30 days on test. Significantly higher (p Evaluation of blood cell morphology did not suggest any compound-related effects. After 30 days on test, spherocytosis and poikilocytosis were seen in blood smears of animals from most groups. Increased polychromasia was observed in one male control rat (# 613), while decreased polychromasia was see in two female 3000 ppm rats (# 719 and 720). Howell-Jolly bodies in the blood and anisocytosis were also noted for Rat # 720. After 90 days on test, poikilocytosis was seen in animals from all groups. Anisocytosis was noted in animals from the control, 500, and 1500 ppm groups. Microcytosis was seen in one male 1500 ppm rat (# 632) and in one male 500 ppm rat (#624) and spherocytosis was seen in two male 1500 ppm rats (# 631 and 638).

CLINICAL CHEMISTRY
After 30 days on test, mean sodium concentrations for the male and female 3000 ppm groups were significantly lower (p After 90 days on test, mean albumin and total protein concentrations for the 3000 ppm female group were significantly lower (p
URINALYSIS
- not examined

NEUROBEHAVIOUR
- not examined

ORGAN WEIGHTS
Mean terminal body weights measured after exsanguination were significantly lower (p kidney weights for the 1500 female and 3000 ppm male and female groups were also significantly lower (p

GROSS PATHOLOGY
- no exposure related effects were observe in male rats.
- Two females of the 3000 ppm group showed hemorrhage involving the glandular stomach (minimal severity). White discoloration in the non-glandular stomach was also observe for these animals.
- No changes were seen in female rats from the 1500 and 500 ppm groups.

HISTOPATHOLOGY: NON-NEOPLASTIC
- exposure related changes were observed in the nasal passages and stomach of 1500 and 3000 ppm rats
- all male and female 3000 ppm rats and 4/10 male and 6/10 female 1500 ppm rats had necrosis of the olfactory epithelium (mild to moderate for the 3000 ppm group, mild for the 1500 ppm group).
- no lesions were observed in the nasal passages of the 500 ppm group
- 3/10 female rats of the 3000 ppm group had inflammation of the stomach mucosa (glandular or forestomach) of mild to minimal severity; the pathologist concluded that this effect was probably due to stress
- no effects were seen in the low- and mid concentration group
- thymus atrophy was observed in one male of the 3000 ppm group, this lesion was attributed to stress by the pathologist

HISTOPATHOLOGY: NEOPLASTIC (if applicable)
- not examined


OTHER FINDINGS
- No exposure-related effect on epidydimidal or testicular sperm count was observed. Effects on testicular staging or spermatogenic were not evaluated due to the unacceptable condition of tissue.

Dose descriptor:

NOAEC

Effect level:

500 ppm

Based on:

test mat.

Sex:

male/female

Basis for effect level:

other: see 'Remark'

Critical effects observed:

not specified

- overall time-weighted average analytical concentrations:

548.4; 1487.5, 3009.6 ppm for males

547.9, 1487.6, 3008.8 ppm for females

- target analytical concentration for the 500 ppm group was increased to 550 ppm to ensure that exposure concentration was at least 500 ppm at all locations of the eposure chamber

Conclusions:

The no-observed-adverse-effect concentration (NOAEC) for this study is considered to be 500 ppm (2.4 mg/L).

Executive summary:

Male and female Sprague-Dawley rats (15 animals/sex/dose group) were exposed to nominal concentrations of 0, 500, 1500 or 3000 ppm of n-butyl acetate for 6 hours per day, 5 days per week for 13 consecutive weeks. The time-weighted average analytical concentrations were within 10% of the target concentrations. Transient signs of sedation were observed during exposure to the 1500 and 3000 ppm concentrations. Body weights were significantly reduced in the mid and high concentration groups. Feed consumption was significantly lower in the 1500 and 3000 ppm group in comparison to the control group. Organ weights affected: weights of liver, kidneys and spleen were significantly lower for the males of the highest concentration goup. Testes and adrenal gland weights for the mid and high concentration groups and the lung weights for the 3000 ppm males were significantly higher than for the control group. Additionally, effects on the stomach (probably stress related) and pulmonary system were observed: Females of the highest concentration group showed signs of irritation of the glandular stomach and necrosis in the non-glandular stomach. Some rats of the 1500 and 3000 ppm group showed degeneration of the olfactory epithelium along the dorsal medial meatus and ethmotubinates of the nasal passages. The severity was mild to moderate for the 3000 ppm group and minimal to mild for the 1500 ppm group. There was no systemic, organ specific toxicity. The no-observed-adverse-effect concentration (NOAEC) for this study is 500 ppm (2.4 mg/L).

Long term local respiratory tract irritation was also apparent at the two higher dose levels in this study but no local effects were identified in the 500 ppm (NOAEC) group.

Endpoint conclusion

Endpoint conclusion:

adverse effect observed

Dose descriptor:

NOAEC

2 400 mg/m³

Study duration:

subchronic

Species:

rat

Quality of whole database:

A reliable modern guideline-compliant 90-day study is supported by a reliable dose-ranging study; studies were performed using the read-across substance n-butyl acetate.

Repeated dose toxicity: dermal - systemic effects

Endpoint conclusion

Endpoint conclusion:

no study available

Repeated dose toxicity: dermal - local effects

Endpoint conclusion

Endpoint conclusion:

no study available

Additional information

Male and female Sprague-Dawley rats (15 animals/sex/dose group) were exposed to nominal concentrations of 0, 500, 1500 or 3000 ppm of n-butyl acetate for 6 hours per day, 5 days per week for 13 consecutive weeks. The time-weighted average analytical concentrations were within 10% of the target concentrations. Transient signs of sedation were observed during exposure to the 1500 and 3000 ppm concentrations. Body weights were significantly reduced in the mid and high concentration groups. Feed consumption was significantly lower in the 1500 and 3000 ppm group in comparison to the control group. Organ weights affected: weights of liver, kidneys and spleen were significantly lower for the males of the highest concentration group. Testes and adrenal gland weights for the mid and high concentration groups and the lung weights for the 3000 ppm males were significantly higher than for the control group. Additionally, effects on the stomach (probably stress related) and pulmonary system were observed: Females of the highest concentration group showed signs of irritation of the glandular stomach and necrosis in the non-glandular stomach.

Some rats of the 1500 and 3000 ppm group showed degeneration of the olfactory epithelium along the dorsal medial meatus and ethmoturbinates of the nasal passages. The severity was mild to moderate for the 3000 ppm group and minimal to mild for the 1500 ppm group. There was no systemic, organ specific toxicity. The no-observed-adverse-effect concentration (NOAEC) for this study is 500 ppm (2.4 mg/L). Local long term inhalation hazard was identified as possible upper respiratory tract irritation.

Justification for selection of repeated dose toxicity inhalation - systemic effects endpoint:

Study of longest duration in the preferred species

Repeated dose toxicity: inhalation - systemic effects (target organ) digestive: stomach

Justification for classification or non-classification

No effects observed in the subchronic exposure study to justify classification of hexyl acetate for repeated dose toxicity (STOT-RE) according to the CLP Regulation.